Berenberg Bank Reissues Neutral Rating on Novo Nordisk Shares
2 reports, 1 independent
Updated Oct 20
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Berenberg Bank reissued a neutral rating on Novo Nordisk shares. Marketbeat.com reports that twenty-six analysts currently cover the company, with sixteen assigning a hold recommendation, five assigning a buy recommendation, and five assigning a sell recommendation. The average twelve-month price objective among analysts is $59.44.
From dailypolitical.com
Why it matters
Analyst ratings influence investor perception and stock valuation for Novo Nordisk. The company is engaged in intense competition for global market leadership in the obesity and diabetes drug market with Eli Lilly and Company.
From dailypolitical.com
Who's involved
- Berenberg BankIssued a neutral rating on Novo Nordisk shares.
- Novo NordiskThe Danish pharmaceutical company whose shares were rated.
Keep exploring
The entities involved
-
Berenberg Bank
German private bank based in Hamburg
-
Novo Nordisk
Danish pharmaceutical company
Related events
- Berenberg Bank reaffirmed a buy rating on Greencore Group, with MarketBeat aggregating the consensus rating data on May 27, 2026.
- Berenberg Bank reiterated a buy rating for Concurrent Technologies, which is listed on the London Stock Exchange, with data provided by MarketBeat.
- Berenberg Bank lifted its price objective while Jefferies Financial Group issued a hold rating report for discoverIE Group plc.
- Berenberg Bank raised its target price and gave a buy rating for The Gym Group, with the rating reported on the London Stock Exchange.
- Novo Nordisk filed required documents with the SEC regarding stock changes on October 22, 2026.